Your browser is no longer supported. Please, upgrade your browser.
Settings
IMMU Immunomedics, Inc. daily Stock Chart
IMMU [NASD]
Immunomedics, Inc.
Index- P/E- EPS (ttm)-1.70 Insider Own8.06% Shs Outstand180.36M Perf Week7.07%
Market Cap3.85B Forward P/E- EPS next Y-0.86 Insider Trans5.63% Shs Float168.79M Perf Month-5.57%
Income-273.80M PEG- EPS next Q-0.24 Inst Own80.60% Short Float11.78% Perf Quarter-16.18%
Sales2.20M P/S1750.31 EPS this Y-21.70% Inst Trans0.62% Short Ratio12.46 Perf Half Y30.98%
Book/sh2.24 P/B9.53 EPS next Y21.10% ROA-80.90% Target Price35.83 Perf Year84.21%
Cash/sh3.54 P/C6.03 EPS next 5Y- ROE-258.50% 52W Range8.68 - 27.33 Perf YTD32.12%
Dividend- P/FCF- EPS past 5Y-65.00% ROI-33.60% 52W High-25.72% Beta2.09
Dividend %- Quick Ratio14.80 Sales past 5Y-15.40% Gross Margin71.50% 52W Low133.87% ATR1.03
Employees185 Current Ratio14.80 Sales Q/Q-33.30% Oper. Margin- RSI (14)43.81 Volatility5.75% 4.70%
OptionableYes Debt/Eq0.05 EPS Q/Q-35.20% Profit Margin- Rel Volume0.55 Prev Close21.35
ShortableYes LT Debt/Eq0.05 EarningsAug 23 AMC Payout- Avg Volume1.60M Price20.30
Recom1.50 SMA20-3.58% SMA50-10.10% SMA2001.22% Volume490,640 Change-4.92%
Sep-17-18Initiated Goldman Buy $36
Jun-07-18Initiated B. Riley FBR, Inc. Buy $53
May-05-17Upgrade Wells Fargo Market Perform → Outperform
Oct-06-16Resumed Jefferies Buy
Jun-21-16Downgrade Wells Fargo Outperform → Market Perform
May-06-16Upgrade Jefferies Hold → Buy
Dec-04-15Downgrade Wells Fargo Outperform → Market Perform
Jul-29-15Downgrade Jefferies Buy → Hold
Aug-27-14Downgrade R. F. Lafferty Buy → Neutral $4
Jan-08-14Initiated Chardan Capital Markets Buy $9
Oct-02-13Reiterated Oppenheimer Outperform $6 → $8
Sep-10-13Initiated R. F. Lafferty Buy $8
Jun-03-13Initiated WallachBeth Buy $6
Aug-31-11Initiated Summer Street Research Buy $8
Jul-28-11Initiated Summer Street Research Buy $8
Jul-13-11Resumed Brean Murray Buy $8
May-17-11Initiated Oppenheimer Outperform $6
Feb-23-11Initiated Wedbush Outperform $6
Jul-03-07Initiated Brean Murray Buy $8
Feb-20-07Initiated Lazard Capital Buy $6
Oct-12-18 09:15AM  Detailed Research: Economic Perspectives on Graco, Immunomedics, Concert Pharmaceuticals, Macquarie Infrastructure, Systemax, and Service Corporation International What Drives Growth in Today's Competitive Landscape GlobeNewswire
08:00AM  Today's Research Reports on Trending Tickers: Amarin and Immunomedics ACCESSWIRE
Oct-11-18 01:26AM  Edited Transcript of IMMU earnings conference call or presentation 23-Aug-18 9:00pm GMT Thomson Reuters StreetEvents
Oct-04-18 08:33AM  Implied Volatility Surging for Immunomedics (IMMU) Stock Options Zacks
Sep-12-18 08:00AM  Immunomedics and Samsung BioLogics Announce Strategic Manufacturing Partnership GlobeNewswire
Sep-11-18 10:23AM  Here's Why Immunomedics Jumped 11.8% in August Motley Fool
Aug-28-18 08:00AM  Today's Research Reports on Trending Tickers: Tetraphase Pharmaceuticals and Immunomedics ACCESSWIRE +7.00%
08:00AM  Immunomedics Announces Participation in Upcoming Healthcare Conferences GlobeNewswire
Aug-24-18 08:47AM  The Daily Biotech Pulse: Immunomedics' Bottom-Line Miss; Kala, Regeneron Await FDA Verdict Benzinga
Aug-23-18 05:14PM  Immunomedics: Fiscal 4Q Earnings Snapshot Associated Press
04:00PM  Immunomedics Announces Fourth Quarter and Fiscal Year 2018 Results and Provides Corporate Update GlobeNewswire
03:00PM  Immunomedics, Inc. to Host Earnings Call ACCESSWIRE
08:23AM  The Daily Biotech Pulse: Novartis Breast Cancer Trial Meets Endpoint, Medpace's Offering, Dexcom Buys TypeZero Benzinga
08:00AM  Today's Research Reports on Trending Tickers: Immunomedics and Global Blood Therapeutics ACCESSWIRE
Aug-16-18 04:35PM  Immunomedics to Report Fourth Quarter and Fiscal Year 2018 Results and Host Conference Call and Webcast on August 23, 2018 GlobeNewswire
Aug-13-18 08:00AM  3 Biotech Stock Favorites to Bet on Today: Top Analysts TheStreet.com
Aug-10-18 07:40AM  Factors of Influence in 2018, Key Indicators and Opportunity within Immunomedics, Vertex Pharmaceuticals, Ralph Lauren, Alliant Energy, TreeHouse Foods, and Lincoln National New Research Emphasizes Economic Growth GlobeNewswire
Jul-30-18 08:00AM  Immunomedics Announces Multiple Clinical and Preclinical Collaborations With Prominent Cancer Research Institutions GlobeNewswire
Jul-23-18 08:00AM  Immunomedics Announces Clinical Collaboration With AstraZeneca in First-Line Triple-Negative Breast and Urothelial Cancers GlobeNewswire
Jul-18-18 08:00AM  FDA Accepts Biologics License Application for Filing and Grants Priority Review for Sacituzumab Govitecan for the Treatment of Metastatic Triple-negative Breast Cancer GlobeNewswire
Jul-11-18 07:35AM  Complimentary Technical Snapshots on Incyte and Three More Biotech Stocks ACCESSWIRE
Jun-27-18 10:42AM  How Financially Strong Is Immunomedics Inc (NASDAQ:IMMU)? Simply Wall St.
Jun-21-18 04:42PM  [$$] Immunomedics Chairman Buys $19M More in Stock Barrons.com
08:20AM  Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Immunomedics ACCESSWIRE
Jun-15-18 11:39AM  Immunomedics Announces Closing of Public Offering of Common Stock GlobeNewswire
Jun-13-18 08:00AM  Immunomedics Announces Pricing of Public Offering of Common Stock GlobeNewswire
Jun-12-18 02:30PM  The Charts of Immunomedics Look Very Bullish Now TheStreet.com
08:47AM  Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate Benzinga
Jun-11-18 04:13PM  Immunomedics Announces Proposed Public Offering of Common Stock GlobeNewswire
03:48PM  After-hours buzz: RH, PLAY and more CNBC
Jun-05-18 08:49AM  Immunomedics (IMMU) Soars: Stock Adds 10.3% in Session Zacks
08:20AM  Today's Research Reports on Stocks to Watch: Genomic Health and Immunomedics ACCESSWIRE
Jun-04-18 04:33PM  Why Fossil Group, Companhia Siderurgica Nacional, and Immunomedics Jumped Today Motley Fool +10.26%
04:32PM  Why A Tie-Up With Clovis Helped This Biotech Spike To An 18-Year High Investor's Business Daily
03:20PM  Why Data at ASCO 2018 Sent Immunomedics Shares Soaring Today Motley Fool
01:18PM  5 Biotech Stocks Moving On ASCO Presentations Benzinga
08:00AM  Immunomedics Provides Business Update at the ASCO 2018 Investor Event GlobeNewswire
Jun-03-18 08:00PM  Clovis Oncology and Immunomedics Announce Planned Clinical Collaboration to Study Combination Therapies in Metastatic Triple-Negative Breast and Urothelial Cancers GlobeNewswire
10:15AM  Immunomedics Reveals Promising Data for Sacituzumab Govitecan in Patients Heavily Pretreated for Metastatic Estrogen Receptor-Positive Breast Cancer GlobeNewswire
Jun-01-18 08:00AM  Immunomedics Announces Pivotal Study of Sacituzumab Govitecan in Patients With Locally Advanced or Metastatic Urothelial Cancer GlobeNewswire
May-30-18 08:00AM  Immunomedics to Present at Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-21-18 08:00AM  Immunomedics Submits Biologics License Application For Sacituzumab Govitecan To The U.S. Food and Drug Administration GlobeNewswire
May-18-18 04:03AM  Edited Transcript of IMMU earnings conference call or presentation 9-May-18 9:00pm GMT Thomson Reuters StreetEvents
May-17-18 12:43PM  Immunomedics Inc (NASDAQ:IMMU): Time For A Financial Health Check Simply Wall St. +7.12%
08:00AM  Today's Research Reports on Trending Tickers: Immunomedics and Rite Aid ACCESSWIRE
May-16-18 05:01PM  Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer GlobeNewswire
May-09-18 04:24PM  Immunomedics: Fiscal 3Q Earnings Snapshot Associated Press
04:00PM  Immunomedics Announces Third Quarter Fiscal 2018 Results and Provides Corporate Update GlobeNewswire
07:30AM  Analysis: Positioning to Benefit within Entergy, Schneider National, C.H. Robinson Worldwide, PTC Therapeutics, Guess?, and Immunomedics  Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
May-02-18 12:01PM  Harry Boxers four biotech stocks to watch today MarketWatch
08:00AM  Immunomedics to Report Third Quarter Fiscal 2018 Results and Host Conference Call and Webcast on May 9, 2018 GlobeNewswire
May-01-18 08:45AM  Immunomedics (IMMU) in Focus: Stock Moves 7.9% Higher Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Heat Biologics and Immunomedics ACCESSWIRE
Apr-25-18 12:15PM  Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (mBC) at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
Apr-17-18 10:21AM  When Will Immunomedics Inc (NASDAQ:IMMU) Become Profitable? Simply Wall St.
Apr-13-18 08:20AM  Todays Research Reports on Trending Tickers: Exact Sciences and Immunomedics ACCESSWIRE
Apr-11-18 08:30AM  Todays Research Reports on Trending Tickers: Neuralstem and Immunomedics ACCESSWIRE
Apr-09-18 08:00AM  Immunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical Officer GlobeNewswire
Mar-27-18 08:25AM  Todays Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Immunomedics ACCESSWIRE
Mar-05-18 08:00AM  Immunomedics to Present at Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Feb-26-18 06:06PM  Edited Transcript of IMMU earnings conference call or presentation 8-Feb-18 10:00pm GMT Thomson Reuters StreetEvents
Feb-15-18 08:00AM  Immunomedics to Participate in RBC Capital Markets 2018 Global Healthcare Conference GlobeNewswire
07:30AM  Fennec Pharma (FENC): The Most Likely Acquisition Target in Healthcare with 200-300% Upside? ACCESSWIRE
Feb-14-18 07:30AM  Blog Exposure - FDA Accepts Amicus Therapeutics NDA for Migalastat for Treatment of Fabry Disease ACCESSWIRE
Feb-13-18 03:49PM  8 Companies That Could Disappear by 2019 InvestorPlace
Feb-09-18 05:01AM  Immunomedics reports 2Q loss Associated Press
Feb-08-18 04:15PM  Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update GlobeNewswire
Feb-06-18 08:00AM  Immunomedics to Report Second Quarter Fiscal 2018 Results and Host Conference Call and Webcast on February 8, 2018 GlobeNewswire
Jan-31-18 08:20AM  New Research: Key Drivers of Growth for Cavco Industries, National Commerce, The Providence Service, Cisco, Immunomedics, and Emergent Biosolutions Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-17-18 07:00AM  Best ETFs for 2018: The SPDR S&P Biotech ETF (XBI) Will Continue to Rock InvestorPlace
Jan-11-18 08:00AM  Immunomedics Announces Agreement with University of Wisconsin Carbone Cancer Center to Expand Sacituzumab Govitecan (IMMU-132) into Prostate Cancer GlobeNewswire
Jan-10-18 08:00AM  Todays Research Reports on Stocks to Watch: Immunomedics, Inc. and Axsome Therapeutics ACCESSWIRE
Jan-08-18 08:30AM  Immunomedics and Royalty Pharma Announce Royalty Funding and Stock Purchase Agreements Totalling $250 Million GlobeNewswire
Jan-04-18 08:45AM  Immunomedics to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-17 11:34AM  Harry Boxer: These two marijuana stocks are climbing higher MarketWatch
Dec-22-17 11:41AM  ETFs with exposure to Immunomedics, Inc. : December 22, 2017 Capital Cube +6.08%
Dec-21-17 12:23PM  BlackBerry Among Four Stocks Breaking Out Forbes
Dec-13-17 07:02AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Immunomedics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Dec-11-17 01:59PM  ETFs with exposure to Immunomedics, Inc. : December 11, 2017 Capital Cube
Dec-08-17 01:59PM  5 Cheap Biotech Stocks to Snag on the Bounce InvestorPlace
07:45AM  Immunomedics' Data Is Good News for Seattle Genetics, Too Motley Fool
07:16AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : December 8, 2017 Capital Cube
Dec-07-17 08:10AM  Todays Research Reports on Stocks to Watch: Immunomedics and Valeant Pharmaceuticals ACCESSWIRE +16.16%
Dec-06-17 03:58PM  Why Immunomedics, Inc. Is Soaring Today Motley Fool +13.00%
12:10PM  Immunomedics Announces Updated Results With Sacituzumab Govitecan (IMMU-132) In Patients With Relapsed Or Refractory Metastatic Triple-Negative Breast Cancer (mTNBC) GlobeNewswire
Nov-30-17 02:00PM  ETFs with exposure to Immunomedics, Inc. : November 30, 2017 Capital Cube
Nov-29-17 08:04AM  Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q1, 2018 By the Numbers : November 29, 2017 Capital Cube
Nov-28-17 08:05AM  Immunomedics, Full Study Data to be Presented December 6, 2017, BLA Application as Early as 1Q18 ACCESSWIRE
Nov-27-17 08:05AM  Analysis: Positioning to Benefit within Aradigm, General Motors, AT&T, Denbury Resources, Novavax, and Immunomedics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-20-17 07:40AM  Featured Company News - Biohaven Pharma Completed Enrollment in First of Two Pivotal Phase-3 Clinical Trials of Rimegepant for Acute Treatment of Migraine ACCESSWIRE
Nov-16-17 08:43AM  Options Traders Expect Huge Moves in Immunomedics (IMMU) Stock Zacks +8.11%
Nov-15-17 08:38AM  Immunomedics (IMMU) Jumps: Stock Rises 5.4% Zacks +5.31%
Nov-14-17 04:07PM  Edited Transcript of IMMU earnings conference call or presentation 9-Nov-17 10:00pm GMT Thomson Reuters StreetEvents +5.40%
12:44PM  Cowen Bets on Immunomedics Securing Accelerated Approval Even After Decreased Overall Survival Seen in IMMU-132 Abstract SmarterAnalyst
Nov-13-17 04:30PM  Why Sears Holdings, Immunomedics, and J.C. Penney Slumped Today Motley Fool -19.35%
09:30AM  Immunomedics Announces Presentations and Investor Event at the 2017 San Antonio Breast Cancer Symposium GlobeNewswire
07:24AM  Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : November 13, 2017 Capital Cube
Nov-10-17 03:02PM  Why Immunomedics, Inc. Jumped Higher Today Motley Fool +18.77%
08:20AM  Todays Research Reports on Trending Tickers: Endo International and Immunomedics ACCESSWIRE
Nov-09-17 05:21PM  Immunomedics reports 1Q loss Associated Press
Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune, to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with The Bayer Group for the development of epratuzumab; clinical and preclinical collaborations with academic cancer institutions, identifying new cancer indications for sacituzumab govitecan and the biology of the Trop-2 antigen; and research collaboration with the Memorial Sloan Kettering Cancer Center to investigate Sacituzumab Govitecan and Labetuzumab Govitecan in preclinical cancer models. Immunomedics, Inc. has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
venBio Select Advisor LLCDirectorJun 15Buy24.00575,00013,800,00017,514,461Jun 15 02:02 PM
venBio Select Advisor LLCDirectorJun 15Buy23.39200,0004,678,00017,714,461Jun 19 04:05 PM
GOLDENBERG DAVID MDirectorMar 07Sale17.6840,000707,0005,613,252Mar 12 08:32 PM
GOLDENBERG DAVID MDirectorMar 07Sale17.5020,000350,0001,774,285Mar 12 08:32 PM
GOLDENBERG DAVID MDirectorMar 05Sale17.2440,000689,4005,653,252Mar 12 08:32 PM
GOLDENBERG DAVID MDirectorFeb 28Sale17.0917,729302,9895,693,252Mar 12 08:32 PM
MARKISON BRIAN ADirectorNov 20Option Exercise3.1615,00047,40099,178Nov 21 05:00 PM
MARKISON BRIAN ADirectorNov 20Sale11.898,39099,72490,788Nov 21 05:00 PM
venBio Select Advisor LLCDirectorNov 15Buy10.97175,0001,919,75016,064,461Nov 16 11:47 AM
Aghazadeh BehzadDirectorNov 15Buy10.97175,0001,919,75016,064,461Nov 15 05:48 PM
venBio Select Advisor LLCDirectorNov 14Buy10.391,150,00011,948,50015,889,461Nov 16 11:47 AM
Aghazadeh BehzadDirectorNov 14Buy10.391,150,00011,948,50015,889,461Nov 15 05:48 PM